BERGENBIO ANNOUNCES LATE-BREAKING ABSTRACT PRESENTATION AT ECCMID 2021
Bergen, Norway, 10 June 2021 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces that an analysis of its Phase II clinical trial of bemcentinib, a first-in-class selective oral AXL inhibitor, in hospitalised COVID-19 patients has been selected as a late-breaking abstract at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which will take place online from 9 – 12 July 2021. Further details on the presentation will follow. To learn more, visit